Remission Antibodies Point to a New CAR T Strategy Against Acute Myeloid Leukemia

A hard target in blood cancer may be getting clearer

Acute myeloid leukemia has remained one of the most difficult blood cancers to tackle with CAR T cell therapy. The central problem is straightforward but severe: many of the surface proteins that could be used to identify and kill leukemia cells are also present on healthy blood-forming cells. A therapy that clears the cancer but destroys the body’s ability to rebuild normal blood can create an unacceptable tradeoff.

Researchers at Memorial Sloan Kettering Cancer Center now say they have identified a possible way around that barrier. Their work describes a CAR T cell approach aimed at a protein called U5 snRNP200, which is normally found inside the nucleus of a cell but appears unexpectedly on the surface of leukemia cells in about half of patients with acute myeloid leukemia. Because the protein does not appear to be broadly present on healthy cells in the same way, the finding opens a possible path toward more selective targeting.

The study was published in Cancer Discovery and was conducted in animal models. The researchers say the idea emerged from an unusual source: antibodies found in AML patients whose cancers entered long-term remission after bone marrow transplant.

Turning a remission clue into a therapy concept

The team’s approach was built by studying immune responses in patients who had already shown a durable clinical outcome. After bone marrow transplant, some patients developed antibodies that recognized leukemia-associated material. Investigators used those remission-linked antibodies as a guide to identify what the immune system might be seeing on the cancer cells.

That search led to U5 snRNP200. Under ordinary biology, the protein is not expected to function as a classic cell-surface flag. Its appearance on leukemia cells therefore matters for two reasons. First, it gives researchers a marker that may distinguish cancer cells from healthy blood-producing cells. Second, it suggests leukemia may expose internal machinery in ways that can be exploited therapeutically, even if scientists do not yet fully understand why that happens.

The Memorial Sloan Kettering group then engineered CAR T cells to mirror that naturally occurring antibody recognition. In other words, instead of starting from a conventional cancer target that is already well known, they reverse-engineered what successful patient immune responses were already doing.

Why the selectivity question matters so much in AML

CAR T treatments have transformed care in some blood cancers, but AML has resisted the same progress. The disease develops in the bone marrow and disrupts normal blood production. That means off-target effects are not a peripheral issue. They are the issue.

If a target is shared with healthy progenitor cells, a therapy can erase the marrow’s capacity to make new blood. In practical terms, that can leave patients vulnerable to infection, bleeding, anemia, and long-term dependence on intensive medical support. For years, that overlap has narrowed the room for safe engineering.

The new work does not solve AML therapy by itself, but it addresses the exact obstacle that has slowed the field. A target found almost exclusively on leukemia cells would change the risk equation. That is why a protein that seems biologically out of place on the cell surface has become so important.

The researchers also reported a way to make the strategy more potent by coaxing cancer cells to produce more of the surface protein. That suggests the eventual therapy concept may involve not only a cell treatment but also a way to increase the visibility of the target on malignant cells.

Potential reach beyond a single leukemia subtype

The findings may extend beyond acute myeloid leukemia. According to the source report, the engineered cells also showed broad activity against several other leukemia types, including B-cell acute lymphoblastic leukemia and pediatric leukemias that can arise from large genetic rearrangements. That does not mean one product is ready to span multiple diseases, but it does suggest the biology may be relevant in more than one setting.

That breadth matters because cancer targets that emerge from one disease often fail to translate elsewhere. Here, the early signal points in the opposite direction. If the target truly reflects a broader vulnerability in leukemia cells, the platform could become more flexible than a typical niche therapy.

There are still fundamental questions. Researchers said they do not yet know why U5 snRNP200 reaches the cell surface. That missing mechanism is important for both safety and durability. If surface expression varies over time or under treatment pressure, a therapy built around it could face escape routes. If expression can be increased in a controlled way, the strategy may become more reliable.

Promising, but still early

The study remains preclinical. Animal-model success does not guarantee that a treatment will behave the same way in humans, especially in diseases as heterogeneous as AML. Manufacturing, dosing, toxicity, persistence of engineered cells, and relapse patterns all remain open questions.

Still, the work stands out because it reframes where cancer targets can come from. Instead of relying only on standard tumor profiling, the researchers extracted a lesson from patients who had already done unexpectedly well. That is a notable shift in logic: the immune system of remission patients may contain a map to targets that standard discovery methods overlook.

For AML, where the search for a safe CAR T target has repeatedly hit the same biological wall, even a credible opening is significant. The new results do not yet amount to a clinical breakthrough, but they identify a route worth following. If the target proves durable and selective in human testing, a long-stalled therapeutic area could finally begin to move.

This article is based on reporting by Medical Xpress. Read the original article.